Bezafibrate Pharmacology 

Bezafibrate
Bezafibrate
Fibrate drug, pan-Peroxisome Proliferator-Activated Receptor (pan-PPAR) activator.Antilipemic agent.
Fibrate drug, pan-Peroxisome Proliferator-Activated Receptor (pan-PPAR) activator.Antilipemic agent.
The drug lowers circulating triglyceride levels by activating lipoprotein lipase which is a key enzyme in the degradation of VLDL (very low density lipoprotein) cholesterol. This effect is exerted through paroxisome proliferator-activated receptor alpha (PPARalpha) which enhances lipoprotein lipase synthesis and fatty acid oxidation. It also reduces hepatic triglyceride synthesis. It also reduces VLDL levels and increases HDL (high density lipoprotein) cholesterol. The increase in HDL cholesterol is partly due to transfer of surface lipid components from catabolised VLDL to HDL and also due to increased production of HDL apoproteins by liver. The small dense LDL have been shifted to larger less dense particles. It is highly effective in mixed hyperlipoproteinemia (type III, IV, and V) also have some actions in hypercholesterolemia. It decreases circulating fibrinogen and glucose levels. It slows the atherosclerotic process.
The drug lowers circulating triglyceride levels by activating lipoprotein lipase which is a key enzyme in the degradation of VLDL (very low density lipoprotein) cholesterol. This effect is exerted through paroxisome proliferator-activated receptor alpha (PPARalpha) which enhances lipoprotein lipase synthesis and fatty acid oxidation. It also reduces hepatic triglyceride synthesis. It also reduces VLDL levels and increases HDL (high density lipoprotein) cholesterol. The increase in HDL cholesterol is partly due to transfer of surface lipid components from catabolised VLDL to HDL and also due to increased production of HDL apoproteins by liver. The small dense LDL have been shifted to larger less dense particles. It is highly effective in mixed hyperlipoproteinemia (type III, IV, and V) also have some actions in hypercholesterolemia. It decreases circulating fibrinogen and glucose levels. It slows the atherosclerotic process.
Absorption: Well absorbed orally, Distribution: Widely distributed in a protein bound form, Metabolism: Metabolized partially by glucuronide conjugation in liver. Excretion: Excreted mainly through urine and a small
portion is excreted through faeces.
Absorption: Well absorbed orally, Distribution: Widely distributed in a protein bound form, Metabolism: Metabolized partially by glucuronide conjugation in liver. Excretion: Excreted mainly through urine and a small
portion is excreted through faeces.
Absorption: Well absorbed orally, Distribution: Widely distributed in a protein bound form, Metabolism: Metabolized partially by glucuronide conjugation in liver. Excretion: Excreted mainly through urine and a small
portion is excreted through faeces.
Absorption: Well absorbed orally, Distribution: Widely distributed in a protein bound form, Metabolism: Metabolized partially by glucuronide conjugation in liver. Excretion: Excreted mainly through urine and a small
portion is excreted through faeces.
N/A
N/A
120minutes
120minutes